SK8572003A3 - Histamine receptor antagonists - Google Patents

Histamine receptor antagonists Download PDF

Info

Publication number: SK8572003A3
Authority: SK; Slovakia
Prior art keywords: histamine; receptor; antagonist; combination; diseases
Prior art date: 2001-01-17

Application number

SK857-2003A

Other languages

English (en)

Slovak (sk)

Inventor

Stephen Jenkinson

Mark Anthony O'reilly

Michael Andrew Trevethick

Original Assignee

Pfizer

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-01-17

Filing date

2002-01-10

Publication date

2004-07-07

2002-01-10 Application filed by Pfizer filed Critical Pfizer

2004-07-07 Publication of SK8572003A3 publication Critical patent/SK8572003A3/sk

Links

229940122236 Histamine receptor antagonist Drugs 0.000 title description 6
NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 claims description 122
102000005962 receptors Human genes 0.000 claims description 65
108020003175 receptors Proteins 0.000 claims description 65
229960001340 histamine Drugs 0.000 claims description 61
239000005557 antagonist Substances 0.000 claims description 57
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 29
208000006673 asthma Diseases 0.000 claims description 20
238000011282 treatment Methods 0.000 claims description 20
206010039085 Rhinitis allergic Diseases 0.000 claims description 16
201000010105 allergic rhinitis Diseases 0.000 claims description 16
201000010099 disease Diseases 0.000 claims description 15
208000035475 disorder Diseases 0.000 claims description 13
239000003814 drug Substances 0.000 claims description 12
102000000543 Histamine Receptors Human genes 0.000 claims description 11
108010002059 Histamine Receptors Proteins 0.000 claims description 11
239000000938 histamine H1 antagonist Substances 0.000 claims description 11
229940124056 Histamine H1 receptor antagonist Drugs 0.000 claims description 10
238000000034 method Methods 0.000 claims description 10
201000009961 allergic asthma Diseases 0.000 claims description 9
230000003042 antagnostic effect Effects 0.000 claims description 8
241000124008 Mammalia Species 0.000 claims description 3
238000004519 manufacturing process Methods 0.000 claims description 3
210000003979 eosinophil Anatomy 0.000 description 14
230000000694 effects Effects 0.000 description 12
239000000203 mixture Substances 0.000 description 12
229920001184 polypeptide Polymers 0.000 description 12
102000004196 processed proteins & peptides Human genes 0.000 description 12
108090000765 processed proteins & peptides Proteins 0.000 description 12
239000000556 agonist Substances 0.000 description 10
230000035605 chemotaxis Effects 0.000 description 10
206010028735 Nasal congestion Diseases 0.000 description 9
239000003396 histamine H4 receptor antagonist Substances 0.000 description 9
OHCQJHSOBUTRHG-KGGHGJDLSA-N FORSKOLIN Chemical compound O=C([C@@]12O)C[C@](C)(C=C)O[C@]1(C)[C@@H](OC(=O)C)[C@@H](O)[C@@H]1[C@]2(C)[C@@H](O)CCC1(C)C OHCQJHSOBUTRHG-KGGHGJDLSA-N 0.000 description 8
210000004027 cell Anatomy 0.000 description 8
150000001875 compounds Chemical class 0.000 description 8
229920000858 Cyclodextrin Polymers 0.000 description 7
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
230000000172 allergic effect Effects 0.000 description 7
208000010668 atopic eczema Diseases 0.000 description 7
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 6
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
206010047115 Vasculitis Diseases 0.000 description 6
239000003446 ligand Substances 0.000 description 6
102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 5
108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 5
230000009286 beneficial effect Effects 0.000 description 5
UCAIEVHKDLMIFL-UHFFFAOYSA-N clobenpropit Chemical compound C1=CC(Cl)=CC=C1CNC(=N)SCCCC1=CNC=N1 UCAIEVHKDLMIFL-UHFFFAOYSA-N 0.000 description 5
229940079593 drug Drugs 0.000 description 5
230000002327 eosinophilic effect Effects 0.000 description 5
238000009472 formulation Methods 0.000 description 5
239000003395 histamine H3 receptor antagonist Substances 0.000 description 5
-1 homologs Substances 0.000 description 5
208000027866 inflammatory disease Diseases 0.000 description 5
239000000243 solution Substances 0.000 description 5
208000024891 symptom Diseases 0.000 description 5
SUZLHDUTVMZSEV-UHFFFAOYSA-N Deoxycoleonol Natural products C12C(=O)CC(C)(C=C)OC2(C)C(OC(=O)C)C(O)C2C1(C)C(O)CCC2(C)C SUZLHDUTVMZSEV-UHFFFAOYSA-N 0.000 description 4
QKDDJDBFONZGBW-UHFFFAOYSA-N N-Cyclohexy-4-(imidazol-4-yl)-1-piperidinecarbothioamide Chemical compound C1CC(C=2NC=NC=2)CCN1C(=S)NC1CCCCC1 QKDDJDBFONZGBW-UHFFFAOYSA-N 0.000 description 4
229920002472 Starch Polymers 0.000 description 4
239000000443 aerosol Substances 0.000 description 4
208000026935 allergic disease Diseases 0.000 description 4
239000000739 antihistaminic agent Substances 0.000 description 4
239000002775 capsule Substances 0.000 description 4
230000001684 chronic effect Effects 0.000 description 4
OHCQJHSOBUTRHG-UHFFFAOYSA-N colforsin Natural products OC12C(=O)CC(C)(C=C)OC1(C)C(OC(=O)C)C(O)C1C2(C)C(O)CCC1(C)C OHCQJHSOBUTRHG-UHFFFAOYSA-N 0.000 description 4
239000012634 fragment Substances 0.000 description 4
239000008101 lactose Substances 0.000 description 4
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
239000000546 pharmaceutical excipient Substances 0.000 description 4
239000000843 powder Substances 0.000 description 4
HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 4
239000007921 spray Substances 0.000 description 4
229940032147 starch Drugs 0.000 description 4
235000019698 starch Nutrition 0.000 description 4
239000008107 starch Substances 0.000 description 4
WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 3
IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 3
201000004624 Dermatitis Diseases 0.000 description 3
108010010803 Gelatin Proteins 0.000 description 3
206010061218 Inflammation Diseases 0.000 description 3
208000019693 Lung disease Diseases 0.000 description 3
IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 3
239000004480 active ingredient Substances 0.000 description 3
150000001413 amino acids Chemical group 0.000 description 3
230000008485 antagonism Effects 0.000 description 3
238000003556 assay Methods 0.000 description 3
229940095074 cyclic amp Drugs 0.000 description 3
239000003085 diluting agent Substances 0.000 description 3
239000008273 gelatin Substances 0.000 description 3
229920000159 gelatin Polymers 0.000 description 3
235000019322 gelatine Nutrition 0.000 description 3
235000011852 gelatine desserts Nutrition 0.000 description 3
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 3
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 3
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 3
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 3
208000026278 immune system disease Diseases 0.000 description 3
230000008595 infiltration Effects 0.000 description 3
238000001764 infiltration Methods 0.000 description 3
230000004054 inflammatory process Effects 0.000 description 3
230000000968 intestinal effect Effects 0.000 description 3
230000001404 mediated effect Effects 0.000 description 3
239000012528 membrane Substances 0.000 description 3
239000002674 ointment Substances 0.000 description 3
235000019271 petrolatum Nutrition 0.000 description 3
238000002360 preparation method Methods 0.000 description 3
230000004044 response Effects 0.000 description 3
206010039083 rhinitis Diseases 0.000 description 3
239000000725 suspension Substances 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
206010014950 Eosinophilia Diseases 0.000 description 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
102100032511 Histamine H4 receptor Human genes 0.000 description 2
241000282412 Homo Species 0.000 description 2
101001016858 Homo sapiens Histamine H4 receptor Proteins 0.000 description 2
102000000743 Interleukin-5 Human genes 0.000 description 2
108010002616 Interleukin-5 Proteins 0.000 description 2
208000014767 Myeloproliferative disease Diseases 0.000 description 2
239000004264 Petrolatum Substances 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
239000008186 active pharmaceutical agent Substances 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
239000008280 blood Substances 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
239000011248 coating agent Substances 0.000 description 2
239000003086 colorant Substances 0.000 description 2
239000002299 complementary DNA Substances 0.000 description 2
239000006071 cream Substances 0.000 description 2
235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 2
206010012601 diabetes mellitus Diseases 0.000 description 2
208000037765 diseases and disorders Diseases 0.000 description 2
239000002552 dosage form Substances 0.000 description 2
229940088679 drug related substance Drugs 0.000 description 2
239000000428 dust Substances 0.000 description 2
239000003995 emulsifying agent Substances 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
239000000796 flavoring agent Substances 0.000 description 2
239000000499 gel Substances 0.000 description 2
238000001802 infusion Methods 0.000 description 2
230000002401 inhibitory effect Effects 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
229940100602 interleukin-5 Drugs 0.000 description 2
230000007794 irritation Effects 0.000 description 2
239000006210 lotion Substances 0.000 description 2
239000000314 lubricant Substances 0.000 description 2
210000004072 lung Anatomy 0.000 description 2
230000004199 lung function Effects 0.000 description 2
235000019359 magnesium stearate Nutrition 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
230000005012 migration Effects 0.000 description 2
238000013508 migration Methods 0.000 description 2
230000004048 modification Effects 0.000 description 2
238000012986 modification Methods 0.000 description 2
239000006199 nebulizer Substances 0.000 description 2
230000001613 neoplastic effect Effects 0.000 description 2
238000007911 parenteral administration Methods 0.000 description 2
239000002245 particle Substances 0.000 description 2
229940066842 petrolatum Drugs 0.000 description 2
229920001223 polyethylene glycol Polymers 0.000 description 2
102000040430 polynucleotide Human genes 0.000 description 2
108091033319 polynucleotide Proteins 0.000 description 2
239000002157 polynucleotide Substances 0.000 description 2
239000003380 propellant Substances 0.000 description 2
230000002685 pulmonary effect Effects 0.000 description 2
229940044551 receptor antagonist Drugs 0.000 description 2
239000002464 receptor antagonist Substances 0.000 description 2
230000001932 seasonal effect Effects 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
239000008247 solid mixture Substances 0.000 description 2
239000002904 solvent Substances 0.000 description 2
239000000126 substance Substances 0.000 description 2
230000002195 synergetic effect Effects 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
230000000699 topical effect Effects 0.000 description 2
230000001052 transient effect Effects 0.000 description 2
239000001993 wax Substances 0.000 description 2
JXYWFNAQESKDNC-BTJKTKAUSA-N (z)-4-hydroxy-4-oxobut-2-enoate;2-[(4-methoxyphenyl)methyl-pyridin-2-ylamino]ethyl-dimethylazanium Chemical compound OC(=O)\C=C/C(O)=O.C1=CC(OC)=CC=C1CN(CCN(C)C)C1=CC=CC=N1 JXYWFNAQESKDNC-BTJKTKAUSA-N 0.000 description 1
ODAOZWTYNWZSBY-SPIKMXEPSA-N (z)-but-2-enedioic acid;6-[2-(1h-imidazol-5-yl)ethylamino]-n-[4-(trifluoromethyl)phenyl]heptanamide Chemical compound OC(=O)\C=C/C(O)=O.OC(=O)\C=C/C(O)=O.C=1N=CNC=1CCNC(C)CCCCC(=O)NC1=CC=C(C(F)(F)F)C=C1 ODAOZWTYNWZSBY-SPIKMXEPSA-N 0.000 description 1
YFMFNYKEUDLDTL-UHFFFAOYSA-N 1,1,1,2,3,3,3-heptafluoropropane Chemical compound FC(F)(F)C(F)C(F)(F)F YFMFNYKEUDLDTL-UHFFFAOYSA-N 0.000 description 1
LVGUZGTVOIAKKC-UHFFFAOYSA-N 1,1,1,2-tetrafluoroethane Chemical compound FCC(F)(F)F LVGUZGTVOIAKKC-UHFFFAOYSA-N 0.000 description 1
DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 description 1
244000215068 Acacia senegal Species 0.000 description 1
241000238876 Acari Species 0.000 description 1
206010027654 Allergic conditions Diseases 0.000 description 1
208000032671 Allergic granulomatous angiitis Diseases 0.000 description 1
201000004384 Alopecia Diseases 0.000 description 1
229920001450 Alpha-Cyclodextrin Polymers 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
206010006474 Bronchopulmonary aspergillosis allergic Diseases 0.000 description 1
208000024172 Cardiovascular disease Diseases 0.000 description 1
208000000362 Chlamydial Pneumonia Diseases 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
208000006344 Churg-Strauss Syndrome Diseases 0.000 description 1
206010009900 Colitis ulcerative Diseases 0.000 description 1
208000035473 Communicable disease Diseases 0.000 description 1
206010011224 Cough Diseases 0.000 description 1
208000011231 Crohn disease Diseases 0.000 description 1
229920002785 Croscarmellose sodium Polymers 0.000 description 1
206010012438 Dermatitis atopic Diseases 0.000 description 1
239000004338 Dichlorodifluoromethane Substances 0.000 description 1
108090000204 Dipeptidase 1 Proteins 0.000 description 1
206010014096 Echinococciasis Diseases 0.000 description 1
208000009366 Echinococcosis Diseases 0.000 description 1
208000018428 Eosinophilic granulomatosis with polyangiitis Diseases 0.000 description 1
206010015958 Eye pain Diseases 0.000 description 1
201000006353 Filariasis Diseases 0.000 description 1
208000018522 Gastrointestinal disease Diseases 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
206010018691 Granuloma Diseases 0.000 description 1
229920000084 Gum arabic Polymers 0.000 description 1
239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
208000017604 Hodgkin disease Diseases 0.000 description 1
208000010747 Hodgkins lymphoma Diseases 0.000 description 1
206010048643 Hypereosinophilic syndrome Diseases 0.000 description 1
206010020751 Hypersensitivity Diseases 0.000 description 1
201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
229940121948 Muscarinic receptor antagonist Drugs 0.000 description 1
UBHYDQAARZKHEZ-UHFFFAOYSA-N N'-[2-(4-iodophenyl)ethyl]carbamimidothioic acid 3-(1H-imidazol-5-yl)propyl ester Chemical compound C=1C=C(I)C=CC=1CCN=C(N)SCCCC1=CN=CN1 UBHYDQAARZKHEZ-UHFFFAOYSA-N 0.000 description 1
206010052437 Nasal discomfort Diseases 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
208000012902 Nervous system disease Diseases 0.000 description 1
208000025966 Neurological disease Diseases 0.000 description 1
208000008589 Obesity Diseases 0.000 description 1
208000001132 Osteoporosis Diseases 0.000 description 1
208000030852 Parasitic disease Diseases 0.000 description 1
208000012641 Pigmentation disease Diseases 0.000 description 1
208000002151 Pleural effusion Diseases 0.000 description 1
206010035664 Pneumonia Diseases 0.000 description 1
206010035673 Pneumonia chlamydial Diseases 0.000 description 1
206010035742 Pneumonitis Diseases 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
229920001214 Polysorbate 60 Polymers 0.000 description 1
206010037660 Pyrexia Diseases 0.000 description 1
208000036071 Rhinorrhea Diseases 0.000 description 1
206010039101 Rhinorrhoea Diseases 0.000 description 1
244000061456 Solanum tuberosum Species 0.000 description 1
235000002595 Solanum tuberosum Nutrition 0.000 description 1
HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
239000004147 Sorbitan trioleate Substances 0.000 description 1
PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
206010042254 Strongyloidiasis Diseases 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
239000000150 Sympathomimetic Substances 0.000 description 1
206010042971 T-cell lymphoma Diseases 0.000 description 1
208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
206010052779 Transplant rejections Diseases 0.000 description 1
206010044608 Trichiniasis Diseases 0.000 description 1
201000006704 Ulcerative Colitis Diseases 0.000 description 1
208000025609 Urogenital disease Diseases 0.000 description 1
240000008042 Zea mays Species 0.000 description 1
235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
235000002017 Zea mays subsp mays Nutrition 0.000 description 1
230000003187 abdominal effect Effects 0.000 description 1
239000000205 acacia gum Substances 0.000 description 1
235000010489 acacia gum Nutrition 0.000 description 1
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
230000004913 activation Effects 0.000 description 1
239000000048 adrenergic agonist Substances 0.000 description 1
208000006778 allergic bronchopulmonary aspergillosis Diseases 0.000 description 1
230000007815 allergy Effects 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
230000002924 anti-infective effect Effects 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
201000008937 atopic dermatitis Diseases 0.000 description 1
230000006472 autoimmune response Effects 0.000 description 1
235000019445 benzyl alcohol Nutrition 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
102000015005 beta-adrenergic receptor activity proteins Human genes 0.000 description 1
108040006818 beta-adrenergic receptor activity proteins Proteins 0.000 description 1
102000006635 beta-lactamase Human genes 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
238000004166 bioassay Methods 0.000 description 1
229960000074 biopharmaceutical Drugs 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
230000037396 body weight Effects 0.000 description 1
210000005013 brain tissue Anatomy 0.000 description 1
208000003362 bronchogenic carcinoma Diseases 0.000 description 1
229910000019 calcium carbonate Inorganic materials 0.000 description 1
FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
239000001569 carbon dioxide Substances 0.000 description 1
229910002092 carbon dioxide Inorganic materials 0.000 description 1
210000000748 cardiovascular system Anatomy 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
235000010980 cellulose Nutrition 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
210000003169 central nervous system Anatomy 0.000 description 1
230000008859 change Effects 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
239000002975 chemoattractant Substances 0.000 description 1
208000037976 chronic inflammation Diseases 0.000 description 1
208000037893 chronic inflammatory disorder Diseases 0.000 description 1
CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 description 1
229960001380 cimetidine Drugs 0.000 description 1
JIJQPEZAVLJZBO-UHFFFAOYSA-N clobenpropit dihydrobromide Chemical compound Br.Br.C1=CC(Cl)=CC=C1CNC(=N)SCCCC1=CNC=N1 JIJQPEZAVLJZBO-UHFFFAOYSA-N 0.000 description 1
238000000576 coating method Methods 0.000 description 1
238000004040 coloring Methods 0.000 description 1
230000000536 complexating effect Effects 0.000 description 1
238000007906 compression Methods 0.000 description 1
230000006835 compression Effects 0.000 description 1
238000011970 concomitant therapy Methods 0.000 description 1
238000013270 controlled release Methods 0.000 description 1
235000005822 corn Nutrition 0.000 description 1
229960001681 croscarmellose sodium Drugs 0.000 description 1
229940097362 cyclodextrins Drugs 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
238000012217 deletion Methods 0.000 description 1
230000037430 deletion Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
239000007933 dermal patch Substances 0.000 description 1
235000019700 dicalcium phosphate Nutrition 0.000 description 1
PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
229940087091 dichlorotetrafluoroethane Drugs 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
230000009429 distress Effects 0.000 description 1
DLNKOYKMWOXYQA-UHFFFAOYSA-N dl-pseudophenylpropanolamine Natural products CC(N)C(O)C1=CC=CC=C1 DLNKOYKMWOXYQA-UHFFFAOYSA-N 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
230000000138 effect on histamine Effects 0.000 description 1
230000001804 emulsifying effect Effects 0.000 description 1
230000007613 environmental effect Effects 0.000 description 1
230000013764 eosinophil chemotaxis Effects 0.000 description 1
239000000945 filler Substances 0.000 description 1
235000019634 flavors Nutrition 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
230000005714 functional activity Effects 0.000 description 1
238000002825 functional assay Methods 0.000 description 1
239000007789 gas Substances 0.000 description 1
239000008103 glucose Substances 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 1
239000008187 granular material Substances 0.000 description 1
238000005469 granulation Methods 0.000 description 1
230000003179 granulation Effects 0.000 description 1
208000020390 granulomatous prostatitis Diseases 0.000 description 1
208000024963 hair loss Diseases 0.000 description 1
230000003676 hair loss Effects 0.000 description 1
150000005828 hydrofluoroalkanes Chemical class 0.000 description 1
239000000017 hydrogel Substances 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
230000002458 infectious effect Effects 0.000 description 1
230000004968 inflammatory condition Effects 0.000 description 1
230000002757 inflammatory effect Effects 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
229910052500 inorganic mineral Inorganic materials 0.000 description 1
208000036971 interstitial lung disease 2 Diseases 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
229940057995 liquid paraffin Drugs 0.000 description 1
208000019423 liver disease Diseases 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
238000002483 medication Methods 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
239000011707 mineral Substances 0.000 description 1
235000010755 mineral Nutrition 0.000 description 1
239000002480 mineral oil Substances 0.000 description 1
235000010446 mineral oil Nutrition 0.000 description 1
230000000510 mucolytic effect Effects 0.000 description 1
201000006417 multiple sclerosis Diseases 0.000 description 1
239000003149 muscarinic antagonist Substances 0.000 description 1
235000020824 obesity Nutrition 0.000 description 1
230000000414 obstructive effect Effects 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
239000003921 oil Substances 0.000 description 1
235000019198 oils Nutrition 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
230000008506 pathogenesis Effects 0.000 description 1
230000037361 pathway Effects 0.000 description 1
230000002085 persistent effect Effects 0.000 description 1
239000008194 pharmaceutical composition Substances 0.000 description 1
239000008024 pharmaceutical diluent Substances 0.000 description 1
229940124531 pharmaceutical excipient Drugs 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
DLNKOYKMWOXYQA-APPZFPTMSA-N phenylpropanolamine Chemical compound C[C@@H](N)[C@H](O)C1=CC=CC=C1 DLNKOYKMWOXYQA-APPZFPTMSA-N 0.000 description 1
229960000395 phenylpropanolamine Drugs 0.000 description 1
208000030773 pneumonia caused by chlamydia Diseases 0.000 description 1
239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
229940113124 polysorbate 60 Drugs 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
238000011533 pre-incubation Methods 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
235000013772 propylene glycol Nutrition 0.000 description 1
201000007094 prostatitis Diseases 0.000 description 1
238000001671 psychotherapy Methods 0.000 description 1
230000000541 pulsatile effect Effects 0.000 description 1
229940044601 receptor agonist Drugs 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000001850 reproductive effect Effects 0.000 description 1
208000023504 respiratory system disease Diseases 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
201000000306 sarcoidosis Diseases 0.000 description 1
210000000697 sensory organ Anatomy 0.000 description 1
230000001568 sexual effect Effects 0.000 description 1
230000019491 signal transduction Effects 0.000 description 1
150000004760 silicates Chemical class 0.000 description 1
201000009890 sinusitis Diseases 0.000 description 1
208000019116 sleep disease Diseases 0.000 description 1
206010041232 sneezing Diseases 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
229940079832 sodium starch glycolate Drugs 0.000 description 1
239000008109 sodium starch glycolate Substances 0.000 description 1
229920003109 sodium starch glycolate Polymers 0.000 description 1
239000001587 sorbitan monostearate Substances 0.000 description 1
235000011076 sorbitan monostearate Nutrition 0.000 description 1
229940035048 sorbitan monostearate Drugs 0.000 description 1
235000019337 sorbitan trioleate Nutrition 0.000 description 1
229960000391 sorbitan trioleate Drugs 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
230000004083 survival effect Effects 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
230000001975 sympathomimetic effect Effects 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
230000017423 tissue regeneration Effects 0.000 description 1
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
238000013519 translation Methods 0.000 description 1
208000003982 trichinellosis Diseases 0.000 description 1
201000007588 trichinosis Diseases 0.000 description 1
CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
229940029284 trichlorofluoromethane Drugs 0.000 description 1
239000003871 white petrolatum Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents

Landscapes

Health & Medical Sciences (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Pulmonology (AREA)
Immunology (AREA)
Epidemiology (AREA)
Otolaryngology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

SK857-2003A 2001-01-17 2002-01-10 Histamine receptor antagonists SK8572003A3 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB0101223.6A GB0101223D0 (en)	2001-01-17	2001-01-17	Histamine receptor antagonists
PCT/IB2002/000042 WO2002056871A2 (fr)	2001-01-17	2002-01-10	Antagonistes de recepteur de l'histamine

Publications (1)

Publication Number	Publication Date
SK8572003A3 true SK8572003A3 (en)	2004-07-07

Family

ID=9906993

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK857-2003A SK8572003A3 (en)	2001-01-17	2002-01-10	Histamine receptor antagonists

Country Status (31)

Country	Link
EP (1)	EP1353657A1 (fr)
JP (1)	JP2004517883A (fr)
KR (1)	KR20030069216A (fr)
CN (1)	CN1486178A (fr)
AP (1)	AP2002002401A0 (fr)
AR (1)	AR032101A1 (fr)
BG (1)	BG107834A (fr)
BR (1)	BR0206502A (fr)
CA (1)	CA2435121A1 (fr)
CR (1)	CR6983A (fr)
CZ (1)	CZ20031853A3 (fr)
DO (1)	DOP2002000325A (fr)
EA (1)	EA200300537A1 (fr)
EC (1)	ECSP034692A (fr)
EE (1)	EE200300335A (fr)
GB (1)	GB0101223D0 (fr)
GT (1)	GT200200003A (fr)
HU (1)	HUP0302767A2 (fr)
IL (1)	IL156087A0 (fr)
IS (1)	IS6818A (fr)
MA (1)	MA26980A1 (fr)
MX (1)	MXPA03006408A (fr)
NO (1)	NO20033223D0 (fr)
OA (1)	OA12440A (fr)
PA (1)	PA8537101A1 (fr)
PL (1)	PL362793A1 (fr)
SK (1)	SK8572003A3 (fr)
SV (1)	SV2003000849A (fr)
TN (1)	TNSN02003A1 (fr)
WO (1)	WO2002056871A2 (fr)
ZA (1)	ZA200304180B (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20030133931A1 (en) *	2001-12-21	2003-07-17	Robin Thurmond	Use of histamine H4 receptor antagonist for the treatment of inflammatory responses
MXPA05002577A (es) *	2002-09-06	2005-09-20	Johnson & Johnson	Uso de moduladores del receptor h4 de histamina para el tratamiento de alergia y asma.
WO2004066960A2 (fr) *	2003-01-28	2004-08-12	Schering Corporation	Combinaison d'antagonistes des recepteurs h1, h3 et h4 en vue du traitement d'inflammations pulmonaires allergiques et non allergiques, de congestions et de rhinites allergiques
US8236786B2 (en) *	2008-08-07	2012-08-07	Pulmagen Therapeutics (Inflammation) Limited	Respiratory disease treatment
WO2013151982A1 (fr)	2012-04-03	2013-10-10	Arena Pharmaceuticals, Inc.	Méthodes et composés utiles pour traiter le prurit, et procédés d'identification desdits composés
WO2013182711A1 (fr)	2012-06-08	2013-12-12	Sensorion	Inhibiteurs des récepteurs h4 pour le traitement des acouphènes
CN119823227B (zh) *	2025-01-14	2025-07-04	广州迪卡德营养科技有限公司	一种益生菌的制备方法及其在治疗过敏性鼻炎中的用途

2001
- 2001-01-17 GB GBGB0101223.6A patent/GB0101223D0/en not_active Ceased
2002
- 2002-01-10 EP EP02732099A patent/EP1353657A1/fr not_active Withdrawn
- 2002-01-10 SK SK857-2003A patent/SK8572003A3/sk unknown
- 2002-01-10 CN CNA028036840A patent/CN1486178A/zh active Pending
- 2002-01-10 BR BR0206502-9A patent/BR0206502A/pt not_active IP Right Cessation
- 2002-01-10 CZ CZ20031853A patent/CZ20031853A3/cs unknown
- 2002-01-10 EA EA200300537A patent/EA200300537A1/ru unknown
- 2002-01-10 WO PCT/IB2002/000042 patent/WO2002056871A2/fr not_active Ceased
- 2002-01-10 KR KR10-2003-7009493A patent/KR20030069216A/ko not_active Ceased
- 2002-01-10 JP JP2002557379A patent/JP2004517883A/ja not_active Withdrawn
- 2002-01-10 EE EEP200300335A patent/EE200300335A/xx unknown
- 2002-01-10 MX MXPA03006408A patent/MXPA03006408A/es unknown
- 2002-01-10 CA CA002435121A patent/CA2435121A1/fr not_active Abandoned
- 2002-01-10 PL PL02362793A patent/PL362793A1/xx not_active Application Discontinuation
- 2002-01-10 IL IL15608702A patent/IL156087A0/xx unknown
- 2002-01-10 OA OA1200300174A patent/OA12440A/en unknown
- 2002-01-10 HU HU0302767A patent/HUP0302767A2/hu unknown
- 2002-01-11 DO DO2002000325A patent/DOP2002000325A/es unknown
- 2002-01-14 PA PA20028537101A patent/PA8537101A1/es unknown
- 2002-01-16 GT GT200200003A patent/GT200200003A/es unknown
- 2002-01-16 AR ARP020100145A patent/AR032101A1/es not_active Application Discontinuation
- 2002-01-16 TN TNTNSN02003A patent/TNSN02003A1/fr unknown
- 2002-01-16 SV SV2002000849A patent/SV2003000849A/es not_active Application Discontinuation
- 2002-01-17 AP APAP/P/2002/002401A patent/AP2002002401A0/en unknown
2003
- 2003-05-15 IS IS6818A patent/IS6818A/is unknown
- 2003-05-21 BG BG107834A patent/BG107834A/bg unknown
- 2003-05-22 CR CR6983A patent/CR6983A/es not_active Application Discontinuation
- 2003-05-29 ZA ZA200304180A patent/ZA200304180B/en unknown
- 2003-07-11 MA MA27233A patent/MA26980A1/fr unknown
- 2003-07-16 NO NO20033223A patent/NO20033223D0/no not_active Application Discontinuation
- 2003-07-17 EC EC2003004692A patent/ECSP034692A/es unknown

Also Published As

Publication number	Publication date
CZ20031853A3 (cs)	2004-07-14
NO20033223L (no)	2003-07-16
PL362793A1 (en)	2004-11-02
NO20033223D0 (no)	2003-07-16
WO2002056871A2 (fr)	2002-07-25
EE200300335A (et)	2003-12-15
SV2003000849A (es)	2003-01-13
IS6818A (is)	2003-05-15
GT200200003A (es)	2002-08-19
KR20030069216A (ko)	2003-08-25
BR0206502A (pt)	2003-10-21
HUP0302767A2 (hu)	2003-11-28
AR032101A1 (es)	2003-10-22
DOP2002000325A (es)	2003-01-31
ZA200304180B (en)	2004-06-15
GB0101223D0 (en)	2001-02-28
EA200300537A1 (ru)	2004-02-26
ECSP034692A (es)	2003-08-29
EP1353657A1 (fr)	2003-10-22
AP2002002401A0 (en)	2002-03-31
JP2004517883A (ja)	2004-06-17
BG107834A (bg)	2004-01-30
PA8537101A1 (es)	2002-08-29
CA2435121A1 (fr)	2002-07-25
MA26980A1 (fr)	2004-12-20
CR6983A (es)	2003-11-25
TNSN02003A1 (fr)	2005-12-23
MXPA03006408A (es)	2003-10-15
OA12440A (en)	2006-05-22
IL156087A0 (en)	2003-12-23
CN1486178A (zh)	2004-03-31

Publication	Publication Date	Title
US11241429B2 (en)	2022-02-08	Method of treating metabolic disorders and depression with dopamine receptor agonists
US11690812B2 (en)	2023-07-04	Methods and compositions for the treatment of steatosis-associated disorders
JP2002511868A (ja)	2002-04-16	増殖性硝子体網膜症を治療するためのカルシウム遮断薬
JP2003525240A (ja)	2003-08-26	糖尿病性腎障害の処置のためのｐｄｇｆ受容体チロシンキナーゼ阻害剤の使用
AU2008259864B2 (en)	2013-08-22	Methods and compositions for administration of Oxybutynin
SK8572003A3 (en)	2004-07-07	Histamine receptor antagonists
CN113438949A (zh)	2021-09-24	用于治疗特发性肺纤维化的组合物和方法
EP2227235B1 (fr)	2014-11-12	Méquitazine pour traiter ou à prévenir la bronchopneumopathie obstructive impliquant les récepteurs h4 de l'histamine
US20040138234A1 (en)	2004-07-15	Histamine receptor antagonists
WO2022054965A1 (fr)	2022-03-17	Composé destiné à être utilisé dans le traitement de la sécheresse buccale
KR20210126515A (ko)	2021-10-20	니클로사마이드를 포함하는 폐고혈압의 예방 및 치료용 조성물
CN1897952B (zh)	2010-12-08	中性白细胞增多抑制剂
AU2002216328A1 (en)	2002-07-30	Histamine receptor antagonists
JP6388791B2 (ja)	2018-09-12	Ｖｐａｃ１受容体活性化剤及びドライマウスの予防薬又は治療薬
HK1060300A (en)	2004-08-06	Histamine receptor antagonists
WO2003101437A2 (fr)	2003-12-11	Methode de traitement de l'asthme

Legal Events

Date	Code	Title	Description
2010-08-09	FB9A	Suspension of patent application procedure